Currently, Lee et al demonstrated that administration of the mimic full-length LEL of CD82 and the selective 10-mer peptide of CD82 LEL markedly suppressed tumor angiogenesis and growth in melanoma, prostate cancer and pancreatic carcinoma (Lee et al., 2021). Here, CD82 is linked to prostate carcinoma.